Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia
- 1 September 2000
- journal article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 26 (6), 657-662
- https://doi.org/10.1038/sj.bmt.1702583
Abstract
There are few reports about the occurrence of hepatic VOD after BMT for severe aplastic anemia (SAA). We prospectively studied 17 patients with SAA after allogeneic BMT for the occurrence and severity of VOD. Plasma levels of protein C, protein S, antithrombin III, vWF, t-PA and PAI-1 were determined before preparative chemotherapy, on the day of marrow infusion, and on days 7, 14 and 21. VOD occurred in seven patients (41.2%) at a median of day 1 (range, day -2 to 15). Five had mild, and two moderate VOD. Platelet transfusion requirements were higher in the patients with VOD. The plasma levels of natural anticoagulants such as protein C, free protein S and antithrombin III decreased significantly on day 0 from the baseline levels. Plasma levels of t-PA, PAI-1 and vWF increased significantly in the early post-transplant period compared to the baseline levels. The mean plasma levels of t-PA on day 7 (P = 0.016) and PAI-1 on days 0 and 7 (P = 0.016, 0.032) were higher in the patients with VOD. In summary, we observed hypercoagulability and a high incidence of VOD after allogeneic BMT for SAA. Levels of t-PA and PAI-1 were significantly higher in the patients with VOD after BMT.Keywords
This publication has 11 references indexed in Scilit:
- Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective studyBone Marrow Transplantation, 1998
- Unusual complications after bone marrow transplantation for dyskeratosis congenitaBritish Journal of Haematology, 1998
- Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activationHepatology, 1996
- Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients.Journal of Clinical Oncology, 1996
- RELATED DONOR LIVER TRANSPLANT FOR VENO-OCCLUSIVE DISEASE FOLLOWING T-DEPLETED UNRELATED DONOR BONE MARROW TRANSPLANTATIONTransplantation, 1996
- Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 PatientsAnnals of Internal Medicine, 1993
- PREDICTABILITY BEFORE TRANSPLANT OF HEPATIC COMPLICATIONS FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATIONTransplantation, 1989
- Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamideCancer, 1988
- Cyclophosphamide-Associated HepatotoxicitySouthern Medical Journal, 1985
- Marrow transplantation in hepatitis‐associated aplastic anemiaAmerican Journal of Hematology, 1984